Form 4: Veracyte CFO Rebecca Chambers Reports Acquisition of 30,200 Shares of Common Stock

Rebecca Chambers, CFO of Veracyte, Inc., reports acquiring 30,200 shares of common stock and disposing of 143,899 shares on March 6, 2025, according to a Form 4 filing with the SEC.

Summary

• This is a Form 4 filing with the SEC by Rebecca Chambers, the Chief Financial Officer of Veracyte, Inc.
• The report details changes in her beneficial ownership of Veracyte's securities.
• On March 6, 2025, Ms. Chambers acquired 30,200 shares of common stock.
• The acquisition was related to restricted stock units.
• Ms. Chambers also disposed of 143,899 shares of common stock.
• Following these transactions, Ms. Chambers directly owns 143,899 shares of Veracyte common stock.
• The restricted stock units vest 25% on March 2, 2026, and then 1/16 per quarter thereafter, contingent upon continued employment.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing. The sentiment is neutral as it simply reports transactions.

Future Outlook

The restricted stock units will continue to vest quarterly after the initial vesting date of March 2, 2026, subject to continued employment.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and alignment with shareholder interests.

Stakeholder Impact

• Shareholders may be interested in the transactions of company insiders as an indicator of management's confidence in the company's future prospects.

Key Dates